Spiral Innovation Partners

Innovation Partners, LLC is a strategic advisory and consulting firm dedicated to accelerating access for medical innovations within the oncology, hematology, and rare disease sectors. The firm provides comprehensive guidance to biopharmaceutical, medical technology, and medical device manufacturers, helping them navigate the complex healthcare system from product development through commercialization. Their services encompass building custom strategies, medical affairs and education, market research, and market and payer access, all aimed at driving awareness, uptake, and adoption of novel therapies and technologies.

Founded in 2011 by Dave Melin, Innovation Partners was established with the vision of connecting manufacturers with key decision-makers globally to expedite patient access to innovative treatments. The firm prides itself on a proven, cross-functional process driven by expert strategists, boasting over 15 years of experience, 75+ brand launches, and 300+ completed projects. Their client base ranges from emerging cancer startups to established pharmaceutical giants in the global oncology business.

Innovation Partners focuses on transforming strong clinical results into compelling narratives that resonate with payers, key opinion leaders (KOLs), and decision-makers. They offer strategic reinforcements to client teams, synthesize insights from various stakeholders, and provide confident guidance on reimbursement and coding strategies to ensure seamless market entry and sustained access. The firm emphasizes relationships, partnerships, humility, inquisitiveness, accountability, and adaptability as core values in their collaborative approach.

The leadership team includes Dave Melin as Chairman, Susan Weidner as Chief Strategy Officer, Kimberly Drager as Executive Director of Business Development, Patricia Tatro as Chief Financial Officer, and Roz Blumenthal as Executive Director of Medical Affairs. This team brings extensive industry experience to support clients in achieving their strategic priorities and ultimately improving patient lives.